MICHAEL JAMES OVERMAN to Gene Expression Profiling
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Gene Expression Profiling.
Connection Strength
0.575
-
Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One. 2013; 8(6):e65144.
Score: 0.189
-
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010 Jan 05; 102(1):144-50.
Score: 0.148
-
Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. J Natl Cancer Inst. 2023 08 08; 115(8):994-997.
Score: 0.095
-
Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol. 2017 Nov 01; 3(11):1546-1553.
Score: 0.064
-
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670.
Score: 0.020
-
Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res. 2021 01 01; 27(1):120-130.
Score: 0.020
-
Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. Oncologist. 2020 11; 25(11):e1807-e1811.
Score: 0.020
-
Increased expression of secreted frizzled related protein 1 (SFRP1) predicts ampullary adenocarcinoma recurrence. Sci Rep. 2020 08 06; 10(1):13255.
Score: 0.019